Abstract
We aimed to develop a cell-level pharmacodynamics-mediated drug disposition (PDMDD) model to analyze in vivo systems where the PD response to a drug has an appreciable effect on the pharmacokinetics (PK). An existing cellular level model of PD stimulation was combined with the standard target-mediated drug disposition (TMDD) model and the resulting model structure was parametrically identifiable from typical in vivo PK and PD data. The PD model of the cell population was controlled by the production rate k in and elimination rate k out which could be stimulated or inhibited by the number of bound receptors on a single cell. Simulations were performed to assess the impact of single and repeated dosing on the total drug clearance. The clinical utility of the cell-level PDMDD model was demonstrated by fitting published data on the stimulatory effects of filgrastim on absolute neutrophil counts in healthy subjects. We postulated repeated dosing as a means of detecting and quantifying PDMDD as a single dose might not be sufficient to elicit the cellular response capable of altering the receptor pool to visibly affect drug disposition. In the absence of any PD effect, the model reduces down to the standard TMDD model. The applications of this model can be readily extended to include chemotherapy-induced cytopenias affecting clearance of endogenous hematopoietic growth factors, different monoclonal antibodies and immunogenicity effects on PK.
Similar content being viewed by others
References
Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248–252
Wang Y-MC, Krzyzanski W, Doshi S et al (2010) Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J 12:729–740. doi:10.1208/s12248-010-9234-9
Roskos LK (2012) The clinical pharmacology of filgrastim and pegfilgrastim. In: Twenty years of G-CSF. Springer, Basel, p 41–60
Quartino AL, Karlsson MO, Lindman H, Friberg LE (2014) Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling. Pharm Res 31:3390–3403. doi:10.1007/s11095-014-1429-9
Farese AM, Cohen MV, Stead RB et al (2012) Pegfilgrastim administered in an abbreviated schedule, significantly improved neutrophil recovery after high-dose radiation-induced myelosuppression in rhesus macaques. Radiat Res 178:403–413. doi:10.1667/RR2900.1
Wang B, Nichol JL, Sullivan JT (2004) Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 76:628–638. doi:10.1016/j.clpt.2004.08.010
Krzyzanski W, Sutjandra L, Perez-Ruixo JJ et al (2013) Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals. Pharm Res 30:655–669. doi:10.1007/s11095-012-0894-2
Bernstein SH, Jusko WJ, Krzyzanski W et al (2002) Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy. J Clin Pharmacol 42:501–511. doi:10.1177/00912700222011553
Yan X, Lowe PJ, Fink M, Berghout A (2012) Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human epoetin alfa and the biosimilar HX575. J Clin Pharmacol. doi:10.1177/0091270011421911/pdf
Doshi S, Krzyzanski W, Yue S et al (2013) Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents. Clin Pharmacokinet 52:1063–1083. doi:10.1007/s40262-013-0098-x
Mould DR, Baumann A, Kuhlmann J et al (2007) Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 64:278–291. doi:10.1111/j.1365-2125.2007.02914.x
Gibiansky L, Frey N (2012) Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. J Pharmacokinet Pharmacodyn 39:5–16. doi:10.1007/s10928-011-9227-z
Perez-Ruixo JJ, Ma P, Chow AT (2013) The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. AAPS J 15:172–182. doi:10.1208/s12248-012-9424-8
Wang B, Ludden TM, Cheung EN et al (2001) Population pharmacokinetic–pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J Pharmacokinet Pharmacodyn 28:321–342. doi:10.1023/A:1011534529622
Krzyzanski W, Wiczling P, Lowe P et al (2010) Population modeling of filgrastim PK–PD in healthy adults following intravenous and subcutaneous administrations. J Clin Pharmacol 50:101S–112S. doi:10.1177/0091270010376966
Mager DE, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22:1589–1596. doi:10.1007/s11095-005-6650-0
Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35:573–591. doi:10.1007/s10928-008-9102-8
Gross AW, Lodish HF (2006) Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 281:2024–2032. doi:10.1074/jbc.M510493200
Sarkar CA, Lauffenburger DA (2003) Cell-level pharmacokinetic model of granulocyte colony-stimulating factor: implications for ligand lifetime and potency in vivo. Mol Pharmacol 63:147–158. doi:10.1124/mol.63.1.147
Krippendorff B-F, Oyarzún DA, Huisinga W (2012) Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling. J Pharmacokinet Pharmacodyn 39:125–139. doi:10.1007/s10928-012-9243-7
Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507–532
Shankaran H, Resat H, Wiley HS (2007) Cell surface receptors for signal transduction and ligand transport: a design principles study. PLoS Comput Biol 3:e101. doi:10.1371/journal.pcbi.0030101
Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457–478. doi:10.1007/BF01061691
Harrold JM, Abraham AK (2014) Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment. J Pharmacokinet Pharmacodyn 41:151. doi:10.1007/s10928-014-9352-6
Borleffs JC, Bosschaert M, Vrehen HM et al (1998) Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects. Clin Ther 20:722–736
Friberg LE, Freijs A, Sandström M, Karlsson MO (2000) Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther 295:734–740
Friberg LE, Karlsson MO (2003) Mechanistic models for myelosuppression. Investig N Drugs. doi:10.1023/A:1023573429626
Layton JE, Shimamoto G, Osslund T et al (1999) Interaction of granulocyte colony-stimulating factor (G-CSF) with its receptor. Evidence that Glu19 of G-CSF interacts with Arg288 of the receptor. J Biol Chem 274:17445–17451
Wiczling P, Lowe P, Pigeolet E et al (2009) Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clin Pharmacokinet 48:817–826. doi:10.2165/11318090-000000000-00000
Kavgaci H, Ozdemir F, Aydin F et al (2002) Endogenous granulocyte colony-stimulating factor (G-CSF) levels in chemotherapy-induced neutropenia and in neutropenia related with primary diseases. J Exp Clin Cancer Res 21:475–479
Demetri GD, Griffin JD (1991) Granulocyte colony-stimulating factor and its receptor. Blood 78:2791–2808
McKenzie SB, Williams JL, Landis-Piwowar K (2014) Clinical laboratory hematology. Prentice Hall, Upper Saddle River
Ramon-Lopez A, Nalda-Molina R, Valenzuela B, Perez-Ruixo JJ (2009) Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients. Pharm Res 26:1952–1962. doi:10.1007/s11095-009-9910-6
Gibaldi M, Perrier D (1982) Pharmacokinetics. Informa HealthCare, New York
Diekmann O, Gyllenberg M, Metz J (2007) Physiologically structured population models: towards a general mathematical theory. In: Takeuchi Y, Iwasa Y, Sato K (eds) Mathematics for ecology and environmental sciences. Springer, Berlin, pp 5–20
Ait-Oudhia S, Vermeulen A, Krzyzanski W (2011) Non-linear mixed effect modeling of the time-variant disposition of erythropoietin in anemic cancer patients. Biopharm Drug Dispos 32:1–15. doi:10.1002/bdd.733
Pastor ML, Laffont CM, Gladieff L et al (2013) Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients. Pharm Res 30:2795–2807. doi:10.1007/s11095-013-1099-z
Yan X, Clemens PL, Puchalski T et al (2015) Target-mediated drug disposition of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitors and immunomodulatory drugs: a population pharmacokinetic analysis. Blood 126:4222
Xu XS, Yan X, Puchalski T et al (2015) Understanding the dose regimen for daratumumab in patients with relapsed or refractory multiple myeloma (MM) after prior proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs): a quantitative pharmacologic perspective. Blood 126:4254
Gibiansky E, Gibiansky L, Carlile DJ et al (2014) Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma and exposure-response in CLL. CPT Pharmacomet Syst Pharmacol 3:1–11. doi:10.1038/psp.2014.42
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The following authors are or were employees of and own stock in Amgen, Inc.: Juan Jose Perez-Ruixo, Liviawati S. Wu, and John M. Harrold. Wojciech Krzyzanski is a consultant for Amgen and received consultation fees for this work.
Appendices
Appendix 1: Clearance of total drug
Since A tot = A P + BV c one can combine Eqs. (2) and (35) to obtain a differential equation
Therefore the elimination rate of the total drug from the body is
Dividing (42) by C yields (40).
Appendix 2: Rapid binding approximation
In many instances receptor binding and dissociation are much faster than the remaining processes described by the model. This results in the inability to uniquely identify the binding parameters. To resolve this problem the rapid binding approximation of the full model (2)–(8) can be applied based on the quasi-equilibrium assumption [16]:
To be able to eliminate the binding parameters k on and k off from the model equations new variables are introduced, the total receptor number/cell (r tot ) and total amount of the drug in the central compartment (A tot ):
Then the model equations become:
where the derivative dN/dt is defined by (7),
and
The total drug and total receptor concentrations in the central compartment are defined as follows
Given that In(t) describes the input rate to the A tot compartments (including bolus doses), the initial conditions for (45)–(47) are
Rights and permissions
About this article
Cite this article
Krzyzanski, W., Harrold, J.M., Wu, L.S. et al. A cell-level model of pharmacodynamics-mediated drug disposition. J Pharmacokinet Pharmacodyn 43, 513–527 (2016). https://doi.org/10.1007/s10928-016-9491-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-016-9491-z